MariTide vs Mazdutide

What the evidence actually compares

MariTide (maridebart cafraglutide) is a long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism. Mazdutide instead activates GLP-1 and glucagon receptors. GIP antagonism should not be described as GIP agonism.

A published randomized phase 2 trial studied MariTide in adults with obesity with or without type 2 diabetes over 52 weeks, using trial-specific weight outcomes. Later-phase MARITIME development does not convert those phase 2 results into a completed peer-reviewed phase 3 comparison. MariTide phase 2, PMID 40549887

Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2

Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.

What cannot be inferred

GLORY-2 and the MariTide phase 2 trial included different groups, regimens and analyses. There is no cited head-to-head trial; their published percentage changes cannot be ranked as if randomized against one another.

MariTide remained investigational in the reviewed sources; no FDA approval for it or mazdutide was verified. Innovent’s Chinese mazdutide approvals are separate from FDA status. The source for the MariTide evidence above is this primary record; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.

This comparison is educational research context, not medical advice or a treatment protocol.